Dulaglutide: An evidence-based review of its potential in the treatment of type 2 diabetes

Core Evidence

Volumn 10, Issue , 2015, Pages 11-21

  Edwards, Krystal L ^a   Minze, Molly G ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

GLP 1 RA; Glucagon like peptide 1 receptor agonist; Incretin mimetic; Type 2 diabetes mellitus therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIPID; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ACUTE PANCREATITIS; CARDIOVASCULAR RISK; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; META ANALYSIS (TOPIC); MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN EXFOLIATION; SYSTOLIC BLOOD PRESSURE; THYROID MEDULLARY CARCINOMA; VOMITING; WEIGHT REDUCTION;

EID: 84920772027     PISSN: 15551741     EISSN: 1555175X     Source Type: Journal    
DOI: 10.2147/CE.S55944     Document Type: Review

References (41)

1. Diabetes facts and figures [webpage on the Internet]. Brussels: International Diabetes Federation; 2014. Available from: http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures. Accessed June 12, 2014.
2. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262-269.
3. Scheen AJ. GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?. Ann Endocrinol (Paris). 2013;74:515-522.
4. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy. 2010;30:609-624.
5. Inzucchi SE, Bergenstal RM, Buse JM, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596.
6. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19: 327-336.
7. National Institute for Health and Clinical Excellence. The Management of Type 2 Diabetes, NICE Clinical Guideline 87, 2009. Available from: https://www.nice.org.uk/guidance/cg87. Accessed June 4, 2014.
8. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728-742.
9. Drucker D, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care. 2010;33: 428-433.
10. DeFranzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
11. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
12. Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide-1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:348-356.
13. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32:1224-1230.
14. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046-2055.
15. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in randomized, double-blind, placebo-controlled study. Diabet Med. 2012;29:1260-1267.
16. Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting, glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426-433.
17. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014;37:2149-2158.
18. Umpierrez GE, Blevins T, Rosenstock J, et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab. 2011;13:418-425.
19. Lorenz M, Evers A, Wagner M. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg Med Chem Lett. 2013;23:4011-4018.
20. Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet]. Evaluation of the therapeutic benefits and harms of exenatide: executive summary of final report A05-23, version 1.0. Available from: https://www.iqwig.de/download/A05-23-Executive-Summary-Evaluation-of-the-therapeutic-benefits-and-harms-of-exenatide.pdf. Accessed November 7, 2014.
21. Umpierrez G, Tofé Povedano S, Pérez Manghi F, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014;37:2168-2176.
22. Wysham C, Blevins T, Arakaki, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159-2167.
23. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomized, open-label, phase 3, non-inferiority trial. Lancet. 2014;384(9951):1349-1357.
24. Eli Lilly and Company. A randomized, parallel-arm, double-blinded study comparing the effect of once-weekly dulaglutide with placebo in patients with type 2 diabetes on sulfonylurea therapy (AWARD-8: Assessment of weekly administration of LY2189265 in diabetes - 8). Available from: http://clinicaltrials.gov/show/NCT01769378. NLM identifier: NCT01769378. Accessed June 4, 2014.
25. Eli Lilly and Company. The efficacy and safety of once-weekly, subcutaneous dulaglutide monotherapy compared with glimepiride in patients with type 2 diabetes mellitus. Available from: http://clinicaltrials.gov/show/ NCT01644500. NLM identifier: NCT01644500. Accessed June 4, 2014.
26. Eli Lilly and Company. The efficacy and safety of once-weekly, subcutaneous dulaglutide compared to once-daily insulin glargine in patients with type 2 diabetes mellitus on metformin and/or a sulfonyluea. Available from: http://clinicaltrials.gov/show/NCT01648582. NLM identifier: NCT01648582. Accessed June 4, 2014.
27. Eli Lilly submits GLP-1 dulaglutide to FDA and unveils injection device [webpage on the Internet]. San Francisco: DiaTribe; 2013. Available from: http://diatribe.org/issues/59/new-now-next/5. Accessed August 13, 2014.
28. Garber AJ. Incretin effects on β-cell function, replication, and mass: the human perspective. Diabetes Care. 2011;34 Suppl 2:s258-s263.
29. Bunck MC, Corner A, Eliasson B, et al. Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care. 2011;34:2041-2047.
30. Guidance for industry diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [webpage on the Internet]. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) [updated 2008]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf. Accessed June 12, 2014.
31. Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 2012;9:95-108.
32. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagonlike peptide-1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011;34:90-95.
33. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:38-47.
34. Eli Lilly and Company. The effect of dulaglutide on major cardiovascular events in patients with type 2 diabetes: Researching cardiovascular events with a weekly incretin in diabetes (REWIND). Available from: http://clinicaltrials.gov/show/NCT01394952. NLM identifier: NCT01394952. Accessed June 12, 2014.
35. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide-1 based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534-539.
36. Monami M, Dicembrini I, Naradini C, Fiordelli I, Mannucci E. Glucagon-like peptide-1 receptor agonists and pancreatitis: a metaanalysis of randomized clinical trials. Diabetes Res Clin Pract. 2014;103:269-275.
37. Li L, Shen J, Bala MM, et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and metaanalysis of randomised and non-randomised studies. BMJ. 2014;348:g2366.
38. Yang L, He Z, Tang X, Liu J. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol. 2013;25:225-231.
39. Eli Lilly and Company. BLA 125469 TRULICITY™ (Dulaglutide) Glucagon-like Peptide-1 (GLP-1) Receptor Agonist: Risk Evaluation and Mitigation Strategy (REMS). Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM417230.pdf. Accessed October 3, 2014.
40. Redbook system [database on the Internet]. Greenwood Village, CO: Truven Health Analytics; 2014. Available from: http://www.redbook.com/redbook/. Accessed November 21, 2014.
41. DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther. 2014;31:202-216.